Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.
Baraf HS, Becker MA, Gutierrez-Urena SR, Treadwell EL, Vazquez-Mellado J, Rehrig CD, Ottery FD, Sundy JS, Yood RA. Baraf HS, et al. Among authors: ottery fd. Arthritis Res Ther. 2013 Sep 26;15(5):R137. doi: 10.1186/ar4318. Arthritis Res Ther. 2013. PMID: 24286509 Free PMC article. Clinical Trial.
Phase I/II study to assess the clinical pharmacology and safety of single ascending and multiple subcutaneous doses of PF-06881894 in women with non-distantly metastatic breast cancer.
Yao HM, Jones SR, Morales S, Moosavi S, Zhang J, Freyman A, Ottery FD. Yao HM, et al. Among authors: ottery fd. Cancer Chemother Pharmacol. 2021 Dec;88(6):1033-1048. doi: 10.1007/s00280-021-04355-6. Epub 2021 Oct 7. Cancer Chemother Pharmacol. 2021. PMID: 34618197 Free PMC article. Clinical Trial.
PF-06881893 (Nivestym™), a Filgrastim Biosimilar, Versus US-Licensed Filgrastim Reference Product (US-Neupogen®): Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers.
Yao HM, Ottery FD, Borema T, Harris S, Levy J, May TB, Moosavi S, Zhang J, Summers M. Yao HM, et al. Among authors: ottery fd. BioDrugs. 2019 Apr;33(2):207-220. doi: 10.1007/s40259-019-00343-8. BioDrugs. 2019. PMID: 30900158 Free PMC article. Clinical Trial.
Translation, cultural adaptation, and assessment of the linguistic and content validity of the PG-SGA to the Spanish linguistic setting by cancer patients and healthcare professionals.
Fuchs-Tarlovsky V, Velasco Gimeno C, Arias-Soberón MD, Silva-Sánchez C, Álvarez-Altamirano K, Vedenne-Gutierrez F, Bejarano-Rosales MP, Motilla de la Cámara M, Castillo-Cruz J, Cuerda Compés C, Ottery FD, Jager-Wittenaar H. Fuchs-Tarlovsky V, et al. Among authors: ottery fd. Nutrition. 2024 Dec;128:112567. doi: 10.1016/j.nut.2024.112567. Epub 2024 Aug 28. Nutrition. 2024. PMID: 39366302
Totality of evidence refutes neoplasm risk with fezolinetant.
Neal-Perry G, Santoro N, Cano A, Nappi RE, Shapiro M, Ottery FD. Neal-Perry G, et al. Among authors: ottery fd. Lancet. 2024 May 18;403(10440):1987-1988. doi: 10.1016/S0140-6736(24)00709-8. Lancet. 2024. PMID: 38762322 No abstract available.
52 results